

2008 Adverse Analytical Findings and Atypical Findings Reported by Accredited Laboratories

Overview of Results

Table A All Sports

Differentiation between Olympic and Non-Olympic Sports	A Samples Analyzed	A Samples Adverse Analytical Findings ¹ (%)	A Samples Atypical Findings ² (%)	A Samples Total Findings* (%)
Olympic Sports	202,067	1,974 (0.98%)	1,741 (0.86%)	3,715 (1.84%)
Non-Olympic Sports	72,548	982 (1.35%)	364 (0.50%)	1,346 (1.86%)
TOTAL	274,615	2,956 (1.08%)	2,105 (0.77%)	5,061 (1.84%)

¹ The **Adverse Analytical Findings (AAF)** in this report are not to be confused with adjudicated or sanctioned **Anti-Doping Rule Violations (ADRV)**. "Adverse Analytical Finding" is defined in the World Anti-Doping Code as "a report from a laboratory or other WADA- approved entity that, consistent with the *International Standard for Laboratories* and related Technical Documents, identifies in a *Sample* the presence of a *Prohibited Substance* or its *Metabolites* or *Markers* (including elevated quantities of endogenous substances) or evidence of the *Use* of a *Prohibited Method*." These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process.

² The **Atypical Findings (ATF)** in this report are not to be confused with adjudicated or sanctioned **Anti-Doping Rule Violations (ADRV)**. "Atypical Finding" is defined in the World Anti-Doping Code as "a report from a laboratory or other WADA-approved entity which requires further investigation as provided by the *International Standard for Laboratories* or related Technical Documents prior to the determination of an *Adverse Analytical Finding*". *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in cases of longitudinal studies on testosterone.

* Includes *Adverse Analytical Findings* and *Atypical Findings*

2008 Adverse Analytical Findings and Atypical Findings Reported by Accredited Laboratories

Comparison of Years 2003 to 2008

Table A1

Olympic and Non-Olympic Statistics

Differentiation between Olympic and Non-Olympic Sports	2003 A Samples Analyzed	2004 A Samples Analyzed	2005 A Samples Analyzed	2006 A Samples Analyzed	2007 A Samples Analyzed	2008 A Samples Analyzed	A Samples Analyzed 2008 vs 2007
Olympic Sports	113,559	128,591	139,836	156,866	174,483	202,067	+15.8%
Non-Olympic Sports	37,651	40,596	43,501	41,277	49,415	72,548	+46.8%
TOTAL	151,210	169,187	183,337	198,143	223,898	274,615	+22.7%

Differentiation between Olympic and Non-Olympic Sports	2003 AAFs ^{1,2}	2004 AAFs ^{1,2}	2005 AAFs ^{1,2}	2006 AAFs ^{1,2}	2007 AAFs ^{1,2}	2008 AAFs ¹	Total Findings*	Total Findings* 2008 vs 2007
Olympic Sports	1,707	2,145	2,958	2,915	3,375	1,974	3,715	+10.1%
Non-Olympic Sports	740	764	951	972	1,027	982	1,346	+31.1%
TOTAL	2,447	2,909	3,909	3,887	4,402	2,956	5,061	+15.0%

Differentiation between Olympic and Non-Olympic Sports	2003 % Total Findings*	2004 % Total Findings*	2005 % Total Findings*	2006 % Total Findings*	2007 % Total Findings*	2008 % AAFs ¹	% Total Findings*	% Total Findings* 2008 vs 2007
Olympic Sports	1.50	1.67	2.12	1.86	1.93	0.98	1.84	-4.66%
Non-Olympic Sports	1.97	1.88	2.19	2.35	2.08	1.35	1.86	-10.58%
Overall	1.62	1.72	2.13	1.96	1.97	1.08	1.84	-6.60%

¹ The *Adverse Analytical Findings* (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process.

² The *Adverse Analytical Findings* (AAF) in years 2003 to 2007 included findings that are defined in 2008 as *Atypical Findings*.

* Includes *Adverse Analytical Findings* and *Atypical Findings*

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table B **Total Results per Laboratory**
(All Sports)

Laboratory		N Samples	N <i>Adverse Analytical Findings</i> ¹	% <i>Adverse Analytical Findings</i> ¹	N <i>Atypical Findings</i> ²	% Total Findings*
1	Sydney, Australia	6,859	43	0.63	89	1.92
2	Seibersdorf, Austria	5,517	55	1.00	71	2.28
3	Ghent, Belgium	6,168	198	3.21	80	4.51
4	Rio de Janeiro, Brazil	4,621	25	0.54	27	1.13
5	Montreal, Canada	16,208	320	1.97	-	1.97
6	Beijing, China	18,548	56	0.30	39	0.51
7	Bogota, Colombia	2,817	51	1.81	40	3.23
8	Havana, Cuba	2,204	44	2.00	33	3.49
9	Prague, Czech Republic	1,976	45	2.28	42	4.40
10	Helsinki, Finland	2,397	33	1.38	35	2.84
11	Paris, France	10,194	316	3.10	192	4.98
12	Cologne, Germany	14,228	172	1.21	239	2.89
13	Dresden, Germany	7,201	37	0.51	103	1.94
14	London, UK	8,075	94	1.16	36	1.61
15	Athens, Greece	5,213	45	0.86	45	1.73
16	Rome, Italy	13,342	114	0.85	215	2.47
17	Tokyo, Japan	5,561	34	0.61	-	0.61
18	Seoul, Korea	3,527	15	0.43	23	1.08
19	Penang, Malaysia	1,796	50	2.78	19	3.84
20	Oslo, Norway	4,468	34	0.76	55	1.99
21	Warsaw, Poland	3,104	54	1.74	70	3.99
22	Lisbon, Portugal	3,444	36	1.05	33	2.00
23	Bloemfontein, South Africa	3,172	42	1.32	15	1.80
24	Moscow, Russia	13,720	121	0.88	123	1.78
25	Barcelona, Spain	3,169	59	1.86	25	2.65
26	Madrid, Spain	7,777	148	1.90	232	4.89
27	Stockholm, Sweden	4,189	68	1.62	67	3.22
28	Lausanne, Switzerland	6,096	76	1.25	74	2.46
29	Bangkok, Thailand	1,659	23	1.39	1	1.45
30	Tunis, Tunisia	1,500	22	1.47	18	2.67
31	Ankara, Turkey	3,705	23	0.62	4	0.73
32	Los Angeles, USA	72,394	405	0.56	60	0.64
33	Salt Lake City, USA	9,198	84	0.91	-	0.91
34	New Delhi, India ³	568	14	2.46	-	2.46
TOTAL		274,615	2,956	1.08%	2,105	1.84%

¹ The *Adverse Analytical Findings* (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process.

² The *Atypical Findings* (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in cases of longitudinal studies on testosterone.

³ New Delhi, India laboratory obtained its accreditation in quarter 4 of 2008

* Includes *Adverse Analytical Findings* and *Atypical Findings*

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table B1 Olympic Sport Results per Laboratory

Laboratory		Samples	N Adverse Analytical Findings ¹	% Adverse Analytical Findings ¹	N Atypical Findings ²	% Total Findings*
1	Sydney, Australia	4,207	26	0.62	52	1.24
2	Seibersdorf, Austria	5,095	48	0.94	67	1.32
3	Ghent, Belgium	5,091	119	2.34	69	1.36
4	Rio de Janeiro, Brazil	4,460	18	0.40	25	0.56
5	Montreal, Canada	15,131	285	1.88	-	0.00
6	Beijing, China	17,856	49	0.27	39	0.22
7	Bogota, Colombia	2,388	35	1.47	37	1.55
8	Havana, Cuba	1,982	13	0.66	30	1.51
9	Prague, Czech Republic	1,652	25	1.51	33	2.00
10	Helsinki, Finland	1,820	17	0.93	25	1.37
11	Paris, France	8,198	214	2.61	151	1.84
12	Cologne, Germany	12,262	121	0.99	211	1.72
13	Dresden, Germany	6,517	30	0.46	96	1.47
14	London, UK	6,065	20	0.33	21	0.35
15	Athens, Greece	4,995	43	0.86	43	0.86
16	Rome, Italy	12,585	100	0.79	205	1.63
17	Tokyo, Japan	4,372	17	0.39	-	0.00
18	Seoul, Korea	2,752	5	0.18	15	0.55
19	Penang, Malaysia	1,247	17	1.36	15	1.20
20	Oslo, Norway	3,545	22	0.62	45	1.27
21	Warsaw, Poland	2,804	36	1.28	59	2.10
22	Lisbon, Portugal	2,926	26	0.89	25	0.85
23	Bloemfontein, South Africa	2,233	24	1.07	11	0.49
24	Moscow, Russia	13,046	104	0.80	117	0.90
25	Barcelona, Spain	2,841	39	1.37	24	0.84
26	Madrid, Spain	6,412	121	1.89	182	2.84
27	Stockholm, Sweden	3,098	50	1.61	41	1.32
28	Lausanne, Switzerland	5,570	52	0.93	61	1.10
29	Bangkok, Thailand	567	11	1.94	1	0.18
30	Tunis, Tunisia	1,322	12	0.91	13	0.98
31	Ankara, Turkey	3,219	11	0.34	4	0.12
32	Los Angeles, USA	33,843	246	0.73	24	0.07
33	Salt Lake City, USA	1,417	5	0.35	-	0.00
34	New Delhi, India ³	549	13	2.37	-	0.00
TOTAL		202,067	1,974	0.98%	1,741	1.84%

¹ The *Adverse Analytical Findings* (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process.

² The *Atypical Findings* (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in cases of longitudinal studies on testosterone.

³ New Delhi, India laboratory obtained its accreditation in quarter 4 of 2008

* Includes *Adverse Analytical Findings* and *Atypical Findings*

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table B2 Non-Olympic Sport Results per Laboratory

Laboratory		Samples	N Adverse Analytical Findings ¹	% Adverse Analytical Findings ¹	N Atypical Findings ²	% Total Findings*
1	Sydney, Australia	2,652	17	0.64	37	2.04
2	Seibersdorf, Austria	422	7	1.66	4	2.61
3	Ghent, Belgium	1,077	79	7.34	11	8.36
4	Rio de Janeiro, Brazil	161	7	4.35	2	5.59
5	Montreal, Canada	1,077	35	3.25	-	3.25
6	Beijing, China	692	7	1.01	-	1.01
7	Bogota, Colombia	429	16	3.73	3	4.43
8	Havana, Cuba	222	31	13.96	3	15.32
9	Prague, Czech Republic	324	20	6.17	9	8.95
10	Helsinki, Finland	577	16	2.77	10	4.51
11	Paris, France	1,996	102	5.11	41	7.16
12	Cologne, Germany	1,966	51	2.59	28	4.02
13	Dresden, Germany	684	7	1.02	7	2.05
14	London, UK	2,010	74	3.68	15	4.43
15	Athens, Greece	218	2	0.92	2	1.83
16	Rome, Italy	757	14	1.85	10	3.17
17	Tokyo, Japan	1,189	17	1.43	-	1.43
18	Seoul, Korea	775	10	1.29	8	2.32
19	Penang, Malaysia	549	33	6.01	4	6.74
20	Oslo, Norway	923	12	1.30	10	2.38
21	Warsaw, Poland	300	18	6.00	11	9.67
22	Lisbon, Portugal	518	10	1.93	8	3.47
23	Bloemfontein, South Africa	939	18	1.92	4	2.34
24	Moscow, Russia	674	17	2.52	6	3.41
25	Barcelona, Spain	328	20	6.10	1	6.40
26	Madrid, Spain	1,365	27	1.98	50	5.64
27	Stockholm, Sweden	1,091	18	1.65	26	4.03
28	Lausanne, Switzerland	526	24	4.56	13	7.03
29	Bangkok, Thailand	1,092	12	1.10	-	1.10
30	Tunis, Tunisia	178	10	5.62	5	8.43
31	Ankara, Turkey	486	12	2.47	-	2.47
32	Los Angeles, USA	38,551	159	0.41	36	0.51
33	Salt Lake City, USA	7,781	79	1.02	-	1.02
34	New Delhi, India ¹	19	1	5.26	-	5.26
TOTAL		72,548	982	1.35%	364	1.86%

¹ The *Adverse Analytical Findings* (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process.

² The *Atypical Findings* (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in cases of longitudinal studies on testosterone.

³ New Delhi, India laboratory obtained its accreditation in quarter 4 of 2008

* Includes *Adverse Analytical Findings* and *Atypical Findings*

2008 Adverse Analytical Findings and Atypical Findings

Reported by Accredited Laboratories

Table C

Olympic Sport Sample Analysis

Sport	Total Samples per Sport	A Sample Adverse Analytical Findings ¹	A Sample Atypical Findings ²	A Sample Total Findings*	% Adverse Analytical Findings ¹
Aquatics	14,020	108	61	169	0.77%
Archery	1,000	13	4	17	1.30%
Athletics	26,984	182	179	361	0.67%
Badminton	1,167	4	11	15	0.34%
Baseball	19,429	216	12	228	1.11%
Basketball	10,572	165	99	264	1.56%
Biathlon	1,297	14	5	19	1.08%
Bobsleigh	1,062	7	19	26	0.66%
Boxing	3,387	75	40	115	2.21%
Canoe / Kayak	3,817	15	44	59	0.39%
Curling	685	7	10	17	1.02%
Cycling	19,436	367	365	732	1.89%
Equestrian	845	15	8	23	1.78%
Fencing	2,143	13	23	36	0.61%
Football	33,445	194	355	549	0.58%
Gymnastics	2,451	12	25	37	0.49%
Handball	3,916	24	42	66	0.61%
Hockey	2,331	18	8	26	0.77%
Ice Hockey	4,748	63	50	113	1.33%
Judo	3,867	25	28	53	0.65%
Luge	142	1	-	1	0.70%
Modern Pentathlon	713	3	-	3	0.42%
Rowing	4,812	27	52	79	0.56%
Sailing	1,330	9	6	15	0.68%
Shooting	2,728	30	15	45	1.10%
Skating	3,187	6	46	52	0.19%
Skiing	3,871	33	36	69	0.85%
Softball	1,253	2	-	2	0.16%
Table Tennis	1,074	4	6	10	0.37%
Taekwondo	1,420	13	4	17	0.92%
Tennis	4,276	20	12	32	0.47%
Triathlon	3,043	40	43	83	1.31%
Volleyball	5,210	35	33	68	0.67%
Weightlifting	7,307	150	76	226	2.05%
Wrestling	4,891	58	21	79	1.19%
Ice Sport ³	93	0	2	2	0.00%
Baseball / Softball ³	115	6	1	7	5.22%
Total	202,067	1,974	1,741	3,715	0.98%

¹ The Adverse Analytical Findings (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process.

² The Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). Atypical Findings may correspond to multiple measurements performed on the same Athlete, such as in cases of longitudinal studies on testosterone.

³ "Baseball/Softball" and "Ice Sport" were designated on Doping Control Forms and unable to assign by single sport or federation.

* Includes Adverse Analytical Findings and Atypical Findings

2008 Adverse Analytical Findings and Atypical Findings Reported by Accredited Laboratories

Table D

Sample Analysis in IOC recognized Sports

Sport	Total per Sport	Adverse Analytical Findings ¹	Atypical Findings ²	A Sample Total Findings*	% Adverse Analytical Findings ¹
Rollersports	537	3	7	10	0.56%
Golf	1,406	13	19	32	0.92%
Karate	635	7	6	13	1.10%
Rugby Union	2,062	17	16	33	0.82%
Squash	402	7	1	8	1.74%
Cricket	658	10	4	14	1.52%
Air Sports	93	1	-	1	1.08%
Bandy	129	4	1	5	3.10%
Billiard Sports	289	7	8	15	2.42%
Boules	141	2	1	3	1.42%
Bowling	224	6	1	7	2.68%
Bridge	47	4	1	5	8.51%
Chess	95	1	1	2	1.05%
Dance Sport	292	2	6	8	0.68%
Korfball	82	3	-	3	3.66%
Life Saving	214	-	-	-	0.00%
Motorcycle Racing	348	9	1	10	2.59%
Mountaineering and Climbing	443	5	10	15	1.13%
Netball	259	-	4	4	0.00%
Orienteering	395	5	9	14	1.27%
Pelote Basque	167	4	7	11	2.40%
Polo	12	-	-	-	0.00%
Powerboating	195	4	1	5	2.05%
Racquetball	30	-	-	-	0.00%
Sumo	92	4	-	4	4.35%
Surfing	116	-	2	2	0.00%
Tug of War	94	1	2	3	1.06%
Underwater Sports	390	1	2	3	0.26%
Water Skiing	138	3	-	3	2.17%
Wushu	113	-	-	-	0.00%
TOTAL	10,098	123	110	233	1.22%

Table E

Sample Analysis in Paralympic Sports

Sport	Total per Sport	Adverse Analytical Findings ¹	Atypical Findings ²	A Sample Total Findings*	% Adverse Analytical Findings ¹
Paralympic Sports	1,529	20	9	29	1.31%

¹ The *Adverse Analytical Findings* (AAF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). These figures may not be identical to sanctioned cases, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process.

² The *Atypical Findings* (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV). *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in cases of longitudinal studies on testosterone.

* Includes *Adverse Analytical Findings* and *Atypical Findings*

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table F Number of Prohibited Substances Identified in Each Drug Class
(All Sports)

Substance Group	Number*	% of all reported findings*
S1. Anabolic Agents	3,259	59.0%
S8. Cannabinoids	496	9.0%
S6. Stimulants	472	8.5%
S5. Diuretics and Other Masking Agents	436	7.9%
S3. Beta-2 Agonists	350	6.3%
S9. Glucocorticosteroids	316	5.7%
S2. Hormones and Related Substances	106	1.9%
P2. Beta-Blockers	31	0.6%
S4. Hormone Antagonists and Modulators	29	0.5%
S7. Narcotics	28	0.5%
M1. Enhancement of Oxygen Transfer	-	0.0%
M2. Chemical and Physical Manipulation	-	0.0%
TOTAL	5,523	

* The *Adverse Analytical Findings (AAF)* and *Atypical Findings (ATF)* in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same *Athlete*. In addition, *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in the case of longitudinal studies on testosterone.

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table G

Substances Identified in Each Drug Class
(All Sports)

S1.1.a. Anabolic Agents - Exogenous AAS	Occurrences	% within drug class
Nandrolone	266	8.2%
Stanozolol	259	7.9%
Methandienone	136	4.2%
Boldenone	93	2.9%
Methyltestosterone	34	1.0%
Drostanolone	32	1.0%
Metenolone	28	0.9%
Mesterolone	17	0.5%
Trenbolone	15	0.5%
Oxandrolone	14	0.4%
Methyltrienolone	5	0.2%
Oxymetholone	5	0.2%
9(10) Dehydronandrolone	5	0.2%
Clostebol	4	0.1%
Oxymesterone	4	0.1%
Dehydrochlormethyltestosterone	3	0.1%
Methasterone	3	0.1%
Danazol	1	0.0%
Desoxymethyltestosterone	1	0.0%
subtotal*	925	

S1.1.b. Anabolic Agents - Endogenous AAS¹	Occurrences	% within drug class
Testosterone (TE ratio)	2,166	66.5%
Exogenous Steroid(s) by IRMS	54	1.7%
Prasterone (DHEA)	25	0.8%
6α-OH-Androstendione	6	0.2%
Androsterone	4	0.1%
Etiocholanolone	3	0.1%
Atypical Profile	3	0.1%
subtotal*	2,261	

S.1.2 Other Anabolic Agents	Occurrences	% within drug class
Clenbuterol	73	2.2%
subtotal*	73	

S.1. All Anabolic Agents	Occurrences
TOTAL *	3,259

¹ Reporting of an Endogenous AAS may be due to detection of a concentration outside normal reference ranges and/or establishment of an exogenous source by GC/C/IRMS.

S2. Hormones and Related Substances	Occurrences	% within drug class
Erythropoetin (EPO)	51	48.1%
Gonadotrophins (hCG)	46	43.4%
Mircera (CERA)	5	4.7%
Erythropoetin (Darbepoetin)	2	1.9%
Insulin	1	0.9%
Gonadotrophins (LH)	1	0.9%
TOTAL *	106	

* The *Adverse Analytical Findings* (AAF) and *Atypical Findings* (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same Athlete. In addition, *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in the case of longitudinal studies on testosterone.

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table G
(cont'd)

Substances Identified in Each Drug Class
(All Sports)

S3. Beta-2 Agonists	Occurrences	% within drug class
Terbutaline	163	46.6%
Formoterol	91	26.0%
Salbutamol	56	16.0%
Salmeterol	30	8.6%
Fenoterol	10	2.9%
TOTAL *	350	

S4. Hormone Antagonists and Modulators	Occurrences	% within drug class
Tamoxifen	12	41.4%
Letrozole	5	17.2%
Anastrozole	4	13.8%
Androst-1,4,6-triene-3,17-dione (ATD)	3	10.3%
Aminoglutethimide	2	6.9%
6-oxo-androstenedione	2	6.9%
Clomiphene	1	3.4%
TOTAL *	29	

S5. Diuretics and Other Masking Agents	Occurrences	% within drug class
Hydrochlorothiazide	137	31.4%
Furosemide	104	23.9%
Finasteride	84	19.3%
Chlorothiazide	27	6.2%
Canrenone	15	3.4%
Indapamide	12	2.8%
Bumetanide	11	2.5%
Epitestosterone	8	1.8%
Triamterene	7	1.6%
Amiloride	6	1.4%
Acetazolamide	6	1.4%
Spironolactone	4	0.9%
Chlortalidone	4	0.9%
Probenecid	3	0.7%
Althiazide	3	0.7%
Torasemide	2	0.5%
Bemithizide	1	0.2%
Piretanide	1	0.2%
Thiazide	1	0.2%
TOTAL *	436	

* The *Adverse Analytical Findings (AAF)* and *Atypical Findings (ATF)* in this report are not to be confused with adjudicated or sanctioned *Anti-Doping Rule Violations (ADRV)*, as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same *Athlete*. In addition, *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in the case of longitudinal studies on testosterone.

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table G
(cont'd)

**Substances Identified in Each Drug Class
(All Sports)**

S6. Stimulants	Occurrences	% within drug class
Amphetamine	166	35.2%
Cocaine	77	16.3%
Ephedrine	54	11.4%
Methylphenidate	40	8.5%
Sibutramine	17	3.6%
Cathine	15	3.2%
4-phenylpiracetam (carphedon)	10	2.1%
Phentermine	8	1.7%
Mephentermine	7	1.5%
Modafinil	6	1.3%
Heptaminol	6	1.3%
Isometheptene	6	1.3%
Norfenfluramine	6	1.3%
Methylenedioxymethamphetamine	6	1.3%
Methamphetamine	5	1.1%
Fenetylline	5	1.1%
Tuaminoheptane	5	1.1%
Oxilofrine	3	0.6%
Etilefrine	3	0.6%
Methylephedrine	3	0.6%
Octopamine	3	0.6%
Strychnine	3	0.6%
Nikethamide	2	0.4%
Selegiline	2	0.4%
Etamivan	2	0.4%
Amfreparamone	2	0.4%
4-Methyl-2-Hexanamine	1	0.2%
Clobenzorex	1	0.2%
Methylamphetamine	1	0.2%
Methoxyphenamine	1	0.2%
Mesocarb	1	0.2%
Levmetamphetamine	1	0.2%
Cropropamide	1	0.2%
Crotetamide	1	0.2%
Phendimetrazine	1	0.2%
Phenmetrazine	1	0.2%
TOTAL *	472	

S7. Narcotics	Occurrences	% within drug class
Morphine	21	75.0%
Methadone	2	7.1%
Hydromorphone	2	7.1%
Heroin	1	3.6%
Oxycodone	1	3.6%
Pethidine	1	3.6%
TOTAL *	28	

* The *Adverse Analytical Findings* (AAF) and *Atypical Findings* (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same *Athlete*. In addition, *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in the case of longitudinal studies on testosterone.

**2008 Adverse Analytical Findings and Atypical Findings
Reported by Accredited Laboratories**

Table G
(cont'd)

**Substances Identified in Each Drug Class
(All Sports)**

S8. Cannabinoids	Occurrences	% within drug class
Cannabinoids	496	100.0%
TOTAL *	496	

S9. Glucocorticosteroids	Occurrences	% within drug class
Budesonide	151	47.8%
Betamethasone	39	12.3%
Prednisolone	37	11.7%
Prednisone	28	8.9%
Triamcinolone Acetonide	16	5.1%
Prednisolone + Prednisone	13	4.1%
Methylprednisolone	14	4.4%
Dexamethasone	14	4.4%
Triamcinolone	4	1.3%
TOTAL *	316	

P2. Beta-Blockers	Occurrences	% within drug class
Propanolol	9	29.0%
Atenolol	6	19.4%
Bisoprolol	5	16.1%
Metoprolol	4	12.9%
Betaxolol	3	9.7%
Acebutalol	2	6.5%
Carvedilol	1	3.2%
Labetalol	1	3.2%
TOTAL *	31	

M1. Enhancement of Oxygen Transfer	Occurrences	% within drug class
Blood Transfusion	-	-
TOTAL *	-	

M2. Chemical and Physical Manipulation	Occurrences	% within drug class
Manipulation	-	-
TOTAL *	-	

* The *Adverse Analytical Findings* (AAF) and *Atypical Findings* (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same *Athlete*. In addition, *Atypical Findings* may correspond to multiple measurements performed on the same *Athlete*, such as in the case of longitudinal studies on testosterone.

2008 Adverse Analytical Findings and Atypical Findings Reported by Accredited Laboratories

Table H **Total Laboratory Adverse Analytical Findings* and Atypical Findings* per Drug Class (All Sports)**

Laboratory	S1. Anabolic Agents	S2. Hormones and Related Substances	S3. Beta-2 Agonists	S4. Hormone Antagonists and Modulators	S5. Diuretics and Other Masking Agents	S6. Stimulants	S7. Narcotics	S8. Cannabinoids	S9. Glucocortico- steroids	P2. Beta- Blockers	Total Findings per Lab	% of total Findings
Sydney, Australia	105	1	6	-	8	2	1	11	3	-	137	2.5%
Seibersdorf, Austria	95	7	9	-	6	6	-	11	4	1	139	2.5%
Ghent, Belgium	146	-	51	3	21	48	5	39	14	1	328	5.9%
Rio de Janeiro, Brazil	31	4	6	-	-	7	-	3	6	-	57	1.0%
Montreal, Canada	91	2	17	5	35	83	-	95	14	-	342	6.2%
Beijing, China	76	2	18	1	11	4	2	-	1	3	118	2.1%
Bogota, Colombia	87	-	-	-	11	4	-	5	10	-	117	2.1%
Havana, Cuba	86	-	-	-	3	3	-	2	-	-	94	1.7%
Prague, Czech Republic	112	4	-	1	14	5	-	12	2	-	150	2.7%
Helsinki, Finland	58	-	8	-	1	-	-	5	4	-	76	1.4%
Paris, France	228	21	24	-	28	18	-	110	118	4	551	10.0%
Cologne, Germany	347	4	7	-	19	25	3	13	2	1	421	7.6%
Kreisch, Germany	107	-	8	-	6	7	1	3	14	1	147	2.7%
London, UK	96	-	7	-	3	27	-	7	-	-	140	2.5%
Athens, Greece	67	1	1	-	5	6	1	8	6	1	96	1.7%
Rome, Italy	116	19	25	-	9	27	3	24	12	-	235	4.3%
Tokyo, Japan	18	-	2	1	6	5	-	2	1	-	35	0.6%
Seoul, Korea	32	-	-	-	6	2	-	-	-	-	40	0.7%
Penang, Malaysia	58	-	1	-	4	1	2	1	2	-	69	1.2%
Oslo, Norway	67	1	1	-	5	9	1	5	-	1	90	1.6%
Warsaw, Poland	119	-	2	1	11	6	-	8	1	1	149	2.7%
Lisbon, Portugal	45	-	1	-	5	7	-	7	3	10	78	1.4%
Bloemfontein, S Africa	27	-	3	1	6	11	-	8	3	-	59	1.1%
Moscow, Russia	180	1	-	2	37	20	-	27	1	3	271	4.9%
Barcelona, Spain	78	3	20	2	13	3	1	6	7	1	134	2.4%
Madrid, Spain	253	5	66	-	7	13	7	27	16	1	395	7.2%
Stockholm, Sweden	75	-	23	-	3	5	-	5	31	-	142	2.6%
Lausanne, Switzerland	88	14	13	1	8	10	1	11	9	-	155	2.8%
Bangkok, Thailand	16	-	-	4	5	-	-	1	-	-	26	0.5%
Tunis, Tunisia	34	-	-	-	1	1	-	5	1	-	42	0.8%
Ankara, Turkey	28	-	-	-	3	1	-	3	1	-	36	0.7%
Los Angeles, USA	274	10	29	5	86	72	-	32	30	2	540	9.8%
Salt Lake City, USA	8	7	2	2	48	30	-	-	-	-	97	1.8%
New Delhi, India	11	-	-	-	2	4	-	-	-	-	17	0.3%
TOTAL PER DRUG CLASS	3,259	106	350	29	436	472	28	496	316	31	5,523	
% of Drug Class	59.0%	1.9%	6.3%	0.5%	7.9%	8.5%	0.5%	9.0%	5.7%	0.6%		

* The Adverse Analytical Findings (AAF) and Atypical Findings (ATF) in this report are not to be confused with adjudicated or sanctioned Anti-Doping Rule Violations (ADRV), as the figures given in this report may contain findings that underwent the Therapeutic Use Exemption (TUE) approval process or multiple findings on the same *Athlete*. In addition, Atypical Findings may correspond to multiple measurements performed on the same *Athlete*, such as in the case of longitudinal studies on testosterone.